GlassScriptPhysician profile
Veronica Padilla
NPI 1912387317
$9,428.09
in general payments reported to CMS, 2019-2025
41 companies · $1,670 in 2025
The $1,670 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,613 · 2022: $2,830 · 2023: $420 · 2024: $895 · 2025: $1,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,838 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,838.01 |
| Education | $147.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,578.99 | 2021-2023 | Wegovy, Ozempic |
| Abbvie INC. | $1,560.30 | 2021-2025 | |
| Lilly USA, LLC | $756.09 | 2021-2023 | Emgality, Jardiance |
| Janssen Biotech, INC. | $637.41 | 2024-2025 | Tremfya, Stelara, Simponi |
| Glaxosmithkline, LLC. | $429.54 | 2021-2023 | Trelegy Ellipta |
| Abbott Laboratories | $382.84 | 2021-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.28 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $345.71 | 2021-2025 | Xifaxan |
| Amarin Pharma, INC. | $291.42 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $264.12 | 2021 | |
| Ardelyx, INC. | $255.54 | 2024-2025 | Ibsrela |
| Amgen INC. | $230.61 | 2021-2023 | Repatha, Otezla |
| Ipsen Biopharmaceuticals, INC | $207.47 | 2024-2025 | Iqirvo, Bylvay |
| Janssen Pharmaceuticals, INC | $206.97 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $195.55 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Padilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.